Poly Medicure to Acquire Italy's Citieffe for Rs 324 Crore

Poly Medicure Ltd., a prominent medical device manufacturing company in India, has made public the signing of a conclusive agreement for the purchase of Medistream SA, the parent of Citieffe SRL

Gleneagles Hospital & Medtronic Host Exclusive Medical Conclave

Gleneagles Hospital Mumbai, in collaboration with global healthcare technology leader Medtronic, hosted an exclusive medical conclave bringing together more than 100 doctors under one roof.The event highlighted the transformative Hub...

Glenmark, Hengrui Ink Deal for HER2-Targeting ADC Therapy

Glenmark Specialty S.A. (GSSA), a fully owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), announced that it and Hengrui Pharma have signed an exclusive license and collaboration agreement for the next-generation HER2-targeting antibody

Apollo Hospitals Expands Genomics Services to Tier-2 Cities

Apollo Hospitals Group is increasing its Genomics services to five additional locations, including Tier-2 cities such as Guwahati, Bhubaneswar, and Indore, to provide more access to genomic testing for the health needs of the country...

Torrent Gets South Africa's Nod for JB Pharma Acquisition

The Competition Commission of South Africa approved Torrent Pharmaceuticals' acquisition of a majority interest in JB Chemicals & Pharmaceuticals from international investment firm KKR on September 22, 2025, giving the company a major boost in its

Marksans Pharma UK Subsidiary Gets MHRA Nod for Moxonidine

Marksans Pharma Ltd declared that its UK subsidiary fully owned by them, Relonchem Limited, has obtained the marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency

Shilpa Medicare Receives EMA Nod for Rivaroxaban Films

Shilpa Medicare Limited from instance, Raichur, Karnataka has been approved by the European Medicines Agency (EMA) to start selling its Rivaroxaban

Sanofi's SAR446268 Receives FDA Fast Track for DM1 Treatment

The US FDA has granted fast track designation to Sanofi’s SAR446268, an experimental gene therapy for myotonic dystrophy type 1 (DM1). This rare progressive neuromuscular disease affects about 1 in 2300 people globally, and has no approved...

Tata 1mg draws investor interest amid valuation standoff

Novo Holdings, which is the principal stakeholder in Danish developer of diabetes and obesity medications, Novo Nordisk, alongside Canadian pension fund CPPIB, Permira and Chrys Capital, has expressed an appetite to invest into Tata Group's online

SRK Family Launches Kriam Pharma for Affordable Healthcare

Shree Ramkrishna Exports (SRK) Family, a worldwide leader in the natural diamond industry, are now in the healthcare sector through the starting of Kriam Pharma which is a project that concentrates on affordable medicines

on the deck


Most Viewed

Editor's Guest


© 2025 India Pharma Outlook. All Rights Reserved.